To include your compound in the COVID-19 Resource Center, submit it here.

Xeljanz: Phase III data

Top-line data from the double-blind, international Phase III OPAL Beyond trial in 395 patients with active psoriatic arthritis who had

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE